HomeCompareERJ vs JNJ

ERJ vs JNJ: Dividend Comparison 2026

ERJ yields 0.08% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.6K in total portfolio value· pulled ahead in Year 4
10 years
ERJ
ERJ
● Live price
0.08%
Share price
$64.52
Annual div
$0.05
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.01
Full ERJ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ERJ vs JNJ

📍 JNJ pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERJJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERJ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERJ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERJ
Annual income on $10K today (after 15% tax)
$6.47/yr
After 10yr DRIP, annual income (after tax)
$0.01/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERJ + JNJ for your $10,000?

ERJ: 50%JNJ: 50%
100% JNJ50/50100% ERJ
Portfolio after 10yr
$25.0K
Annual income
$2,344.70/yr
Blended yield
9.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ERJ
Analyst Ratings
15
Buy
3
Hold
3
Sell
Consensus: Buy
Price Target
$67.00
+3.8% upside vs current
Range: $67.00 — $67.00
Altman Z
18.3
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERJ buys
0
JNJ buys
0
No recent congressional trades found for ERJ or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERJJNJ
Forward yield0.08%2.13%
Annual dividend / share$0.05$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$19.7K$30.3K
Annual income after 10y$0.01$4,689.40
Total dividends collected$8.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$67.00$228.73

Year-by-year: ERJ vs JNJ ($10,000, DRIP)

YearERJ PortfolioERJ Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,704$3.81$10,592$272.30+$112.00ERJ
2$11,455$1.90$11,289$357.73+$166.00ERJ
3$12,258$0.95$12,123$472.89+$135.00ERJ
4← crossover$13,116$0.48$13,141$629.86$25.00JNJ
5$14,035$0.24$14,408$846.81$373.00JNJ
6$15,017$0.12$16,021$1,151.60$1.0KJNJ
7$16,068$0.06$18,122$1,588.22$2.1KJNJ
8$17,193$0.03$20,930$2,228.20$3.7KJNJ
9$18,397$0.01$24,792$3,191.91$6.4KJNJ
10$19,685$0.01$30,274$4,689.40$10.6KJNJ

ERJ vs JNJ: Complete Analysis 2026

ERJStock

Embraer S.A. designs, develops, manufactures, and sells aircrafts and systems in Brazil, North America, Latin America, the Asia Pacific, Brazil, Europe, and internationally. It operates through Commercial Aviation; Defense and Security; Executive Jets; Service & Support; and Other segments. The Commercial Aviation segment designs, develops, and manufactures a variety of commercial aircrafts. The Defense and Security segment engages in the research, development, production, modification, and support for military defense and security aircraft; and offers a range of products and integrated solutions that include radars and special space systems, as well as information and communications systems comprising command, control, communications, computer, intelligence, surveillance, and reconnaissance systems. The Executive Jets segment develops, produces, and sells executive jets. It also leases Legacy 600 and Legacy 650 executive jets in the super midsize and large categories; Legacy 450 and Legacy 500 executive jets in the midlight and midsize categories; Phenom family executive jets in the entry jet and light jet categories; Lineage 1000, an ultra-large executive jet; and Praetor 500 and Praetor 600, disruptive executive jets in the midsize and super midsize categories. The Service & Support segment offers after-service solutions, support, and maintenance, repair, and overhaul services for commercial, executive, and defense aircrafts; provides aircraft components and engines; and supplies steel and composite aviation structures to various aircraft manufacturers. The Other segment is involved in the supply of fuel systems, structural parts, and mechanical and hydraulic systems; and production of agricultural crop-spraying aircraft. The company was formerly known as Embraer-Empresa Brasileira de Aeronáutica S.A. and changed its name to Embraer S.A. in November 2010. Embraer S.A. was incorporated in 1969 and is headquartered in São Paulo, Brazil.

Full ERJ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ERJ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERJ vs SCHDERJ vs JEPIERJ vs OERJ vs KOERJ vs MAINERJ vs ABBVERJ vs MRKERJ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.